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A B S T R A C T
Background
Cystic fibrosis is a genetic disorder which can lead to multiorgan dysfunction. Malabsorption of fat and fat-soluble vitamins (A, D, E,
K) may occur and can cause subclinical deficiencies of some of these vitamins. Vitamin K is known to play an important role in both
blood coagulation and bone formation. Supplementation with vitamin K appears to be one way of addressing the deficiency, but there
is very limited agreement on the appropriate dose and frequency of use of these supplements.
Objectives
To assess the effects of vitamin K supplementation in people with cystic fibrosis and to determine the optimal dose and route of
administration of vitamin K for both routine and therapeutic use.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Trials Register comprising references identified from com-
prehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
Most recent search: 15 April 2010.
Selection criteria
Randomised and quasi-randomised controlled trials of all preparations of vitamin K used as a supplement compared to either no
supplementation (or placebo) at any dose or route and for any duration, in children or adults diagnosed with cystic fibrosis (by sweat
test or genetic testing).
Data collection and analysis
Two authors independently screened papers, extracted trial details and assessed their risk of bias.
Main results
Two trials (total of 32 participants) were included in the review and were assessed as having a moderate risk of bias. One was a dose-
ranging parallel group trial; and the other had a cross-over design, but no separate data were reported for the first intervention period.
Neither of the trials addressed any of the primary outcomes (coagulation, bone formation and quality of life). Both trials reported the
restoration of serum vitamin K and undercarboxylated osteocalcin levels to the normal range after one month of daily supplementation
with 1 mg of vitamin K.
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Authors’ conclusions
Evidence from randomised controlled trials on the benefits of routine vitamin K supplementation for people with CF is currently weak
and limited to two small trials of short duration. However, no harm was found and until further evidence is available, the present
recommendations should be adhered to.
P L A I N L A N G U A G E S U M M A R Y
Vitamin K supplementation for cystic fibrosis
Cystic fibrosis is an inherited condition causing disease most noticeably in the lungs, digestive tract and pancreas. People with cystic
fibrosis often have pancreatic insufficiency which may be linked to deficiencies of fat-soluble vitamins like vitamin K. Vitamin K is
needed for adequate blood clotting, bone formation and some metabolic functions.
This review looked at giving vitamin K supplements to address the effects of deficiency on blood clotting, bone strength and quality
of life in people with cystic fibrosis. We tried to determine the optimal dosage required to prevent this deficiency.
Data from two small trials did not clearly indicate whether giving vitamin K supplements will improve blood clotting, bone strength
or quality of life in people with cystic fibrosis. We were not able to draw firm conclusions from this review and advise that the current
recommendations from the Cystic Fibrosis Foundation and the European Cystic Fibrosis Society should be followed until further
evidence becomes available.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a multisystem disorder that primarily affects
the respiratory and gastrointestinal (GI) systems (Morgan 1999).
It is caused by homozygous presence of a mutation in the gene
encoding the cystic fibrosis transmembrane conductance regulator
(CFTR) protein.
In the UK there are over 8000 people affected by CF and in
the United States of America this figure is approximately 30,000;
most are diagnosed by six months of age and the median survival
has reached the fifth decade of life (Davis 2006; Goss 2004;
Staab 2004). It is the most common, life-threatening, autosomal-
recessively inherited disease in the white population, with a carrier
rate of 1 in 25 and an incidence of 1 in 2500 live births (Ratjen
2003); CF is less common in other ethnic groups, approximately
1 in 46 Hispanics, 1 in 65 Africans and 1 in 90 Asians carry at
least one abnormal CFTR gene (Bobadilla 2002).
The CFTR protein is a chloride ion channel, important in tissues
that produce sweat, digestive juices and mucus. The dominant
symptoms of CF relate to the respiratory andGI systems (Wagener
2003). In the GI system, liver dysfunction, intestinal obstruction
and exocrine pancreatic insufficiency are the most common mor-
bidities. Pancreatic insufficiency (PI) affects up to 90% of people
with CF and causes fat malabsorption (Dodge 2006). Fat-soluble
vitamins (A, D, E and K) are co-absorbed with fat and thus defi-
ciency of these vitamins may occur (Dodge 2006). Hence ,vitamin
K deficiency is well recognised in patients with CF and PI. While
deficiencies may occur from the disease process of CF and from
insufficient supplementation, another additional co-factor is the
long-term use of certain types of antibiotics. These can put some
individuals at additional risk of vitamin K deficiency by altering
intestinal flora which produce vitamin K (Conway 2005). Long-
term effects of bowel resection, an intervention required for in-
testinal obstruction in some newborns with CF and varying de-
grees of liver dysfunction can pose a further additional risk for
vitamin K deficiency (Fuchs 1998).
The manifestations of vitamin K deficiency can range from a mild
subclinical identification (e.g. low levels of vitamin K in the blood)
to widespread coagulopathy (defect in the body’s mechanism for
blood clotting). Such manifestations may include mucosal bleed-
ing (e.g. in the nose, gastro-intestinal system, and in the urine) and
subcutaneous bleeding (e.g. oozing from venipuncture sites and
susceptibility to bruising). Vitamin K is also involved in the cal-
cium binding proteins in the bone and its deficiency is implicated
in defective bone remineralization and thus osteoporosis (Conway
2005).
The majority of CF centres routinely administer vitamins A, D,
and E as supplements from the neonatal period. Vitamin K ad-
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ministration is usually prescribed when clinical deficiencies are
detected or following routine investigations. The limited storage
capacity and rapid metabolic turnover of vitamin K (Olsen 1994)
supports the recommendations for daily rather than weekly sup-
plementation of vitamin K (Beker 1997).
Description of the intervention
Two forms of vitaminK (K1 andK2) occur naturally and synthetic
forms of the vitamin (K3, K4, and K5) are also available. Naturally
occurring vitamin K is found in green vegetables i.e. kale, collards,
spinach and salads (K1 -phytonadione) and a small amount is
made in human gut by bacteria (K2-menaquinones). Therapeutic
vitamin K is available in both water soluble and insoluble forms
(Durie 1994). The enteral forms of vitaminK supplementation are
commonly prescribed. These can be in tablet, ampoule (Borowitz
2002; Cystic Fibrosis Trust 2007) or multivitamin preparations (
Durie 1994).VitaminK can also be administered by intramuscular
(Shearer 1995) or intravenous injections (Verghese 2003).
How the intervention might work
Vitamin K functions as the cofactor of the enzyme vitamin K-
dependent carboxylase. This enzyme catalyses the post-transla-
tion formation of gamma-carboxyglutamyl (Gla) residues in spe-
cific proteins. Vitamin K-dependent proteins are: blood coagu-
lation factors (prothrombin and Factors VII, IX and X); other
plasma proteins (protein C, protein S and protein Z); two pro-
teins from bone (osteocalcin and matrix Gla-protein); and pro-
teins from lung, kidney, spleen, testis, placenta and other tissues
(Uotila 1990).
Blood coagulation requires activation of inactive proenzymes,
hence vitamin K is a vital factor in synthesis of clotting factors and
causes haemostasis in vitamin K-dependant bleeding manifesta-
tions.
Vitamin K-related carboxylation allows the activation of the bone
matrix protein, osteocalcin, resulting in osteoblast function and
bone formation; vitamin-K deficiency impairs this process and
thus impairs bone formation (Okano 2005).
Why it is important to do this review
Vitamin K deficiency is common in CF patients with pancreatic
insufficiency. Supplementation (often oral and occasionally par-
enteral) appears to the most immediate measure to address the
deficiency, although there is limited consensus on the dose and
frequency of supplements for routine or therapeutic use (Rashid
1999). In 1992 the Consensus Committee of the Cystic Fibrosis
Foundation (CFF) suggested a particular dosage (Ramsey 1992);
but the recommendations were later proved ineffectual by another
study (Beker 1997). The 2002 American Consensus Committee
recommended a low-dose supplementation of vitamin K for all
ages (0.3 to 0.5 mg/day), but emphasized that no adverse effects
had been reported at any dosage level of vitamin K (Borowitz
2002). Recent recommendations from Europe and the UK have
suggested varying dose regimens ranging from 0.3 to 1 mg/day
to 10 mg/week (Cystic Fibrosis Trust 2002; Sinaasappel 2002).
There is a suggestion from a recent study that only a higher level
of supplementation can normalise vitamin K levels in people with
CF (Dougherty 2010).
There is no uniform consensus on routine or at-risk vitamin K
supplementation in individuals with CF. There is increasing evi-
dence that the prevalence of vitamin K deficiency in CF is asso-
ciated with an increased morbidity (Rashid 1999). Thus, a sys-
tematic review on vitamin K supplementation in people with CF
could provide evidence to guide clinical practice.
O B J E C T I V E S
To determine the effects of vitamin K supplementation on the
morbidities in people with CF.
To investigate the hypotheses that vitamin K will decrease defi-
ciency-related coagulopathy, increase bone mineral density, de-
crease risk of fractures and improve quality of life in people with
CF.
To determine the optimal dose and route of administration of
vitamin K for people with CF (for both routine and therapeutic
use).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials and quasi-randomised controlled tri-
als.
Types of participants
Children and adults with a diagnosis of CF (defined by sweat test
or genetic testing or both).
Exclusion criteria: Any intervention which may affect the inter-
pretation of the effects of vitamin K or any allergy to vitamin K:
• any anticoagulation in the past three months (will make
interpretation of vitamin K effects on blood coagulation
difficult);
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• bisphosphonates in the past six months (will make
interpretation of vitamin K effects on bone metabolism difficult);
• allergy to vitamin K.
Types of interventions
All preparations of vitamin K used as a supplement compared to
placebo or no supplementation at any dose and for any duration.
Studies comparing different doses and regimens of vitamin Kwere
considered.
Types of outcome measures
Primary outcomes
1. Clinical outcomes related to coagulopathy (Sutor 1995)
i) time to cessation of bleeding manifestations
(symptomatic coagulopathy)
ii) time to normalisation of sub-therapeutic international
normalized ratio (INR) (asymptomatic or sub-clinical
coagulopathy)
2. Bone formation outcome measures
i) bone mineral density at the spine (L1-L4) and the
total hip (measured by dual energy X-ray absorptiometry
(DEXA) scans with z score compared to reference population)
(Borowitz 2002)
ii) reduction in risk of bone fractures
3. Quality of life (e.g. the CFQ-R (Quittner 2000) and the
CFQoL (Gee 2000))
Secondary outcomes
1. Nutritional parameters (including z scores or centiles)
i) weight
ii) height
iii) body mass index (BMI)
2. Adverse events
i) mild (not requiring intervention)
ii) moderate (requiring treatment)
iii) severe (life threatening or requiring hospitalisation)
3. Serum levels
i) serum undercarboxylated osteocalcin (ucOC)
ii) ucOC/cOC (carboxylated osteocalcin) ratio (UCR)
4. Vitamin K-specific laboratory outcomes
i) plasma level of vitamin K1 (measured by high
performance liquid chromatography (HPLC) and fluorescence
detection (Wang 2004)
ii) proteins induced by vitamin K absence or antagonism
factor II (PIVKA II) levels (measured by enzyme-linked
immunosorbent assay (ELISA)) (Belle 1991; Belle 1995)
Search methods for identification of studies
Electronic searches
We identified relevant trials from theGroup’s Cystic Fibrosis Trials
Register using the term: ’vitamin K’.
A systematic search without language restrictions was conducted
using the optimally sensitive strategy developed for the Cochrane
Collaboration to identify all relevant published and unpublished
randomised controlled trials (Lefebvre 2009) in the Cystic Fibro-
sis Trials Register which is compiled from electronic searches of
the Cochrane Central Register of Controlled Trials (Clinical Tri-
als) (updated each new issue of The Cochrane Library), quarterly
searches of MEDLINE, a search of EMBASE to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant sections of the Cystic Fibrosis
and Genetic Disorders Group Module.
Date of the latest search: 15 April 2010.
Searching other resources
The following additional resources were used:
1. the bibliographical references of identified studies were
searched for citations to additional studies;
2. personal contact with corresponding authors of relevant
trials or reviewers and other experts;
3. clinical trials registries: clinicaltrials.gov; Current
Controlled Trials.
Data collection and analysis
Selection of studies
Two review authors (Vanitha Jagannath (VJ) and Zbys Fedorow-
icz (ZF)) independently assessed the abstracts of trials resulting
from the searches. We obtained full text copies of all relevant and
potentially relevant trials, those appearing to meet the inclusion
criteria, and those for which there was insufficient detail in the
title and abstract to make a clear decision. The two authors then
independently assessed the full text papers. There were no dis-
agreements; however, if there are any disagreements on the eligibil-
ity of trials in the future, we will resolve these through discussion
and consensus, or through a third party (Vidhu Thaker (VT)). All
irrelevant records were excluded and details of the trials and the
reasons for their exclusion were noted in the tables (Characteristics
of excluded studies) in RevMan 5 (RevMan 2008).
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Data extraction and management
We entered details for the included trials into the tables (
Characteristics of included studies) in RevMan 5 (RevMan 2008)
and collected outcome data using a pre-determined form designed
for this purpose. Two review authors (VJ, ZF) extracted data in-
dependently and in duplicate and only included these if there was
a consensus; there were no disagreements; if these occur in the fu-
ture, we will resolve them by consulting with a third review author
(VT).
The authors extracted the following details.
1. Trial methods
i) method of allocation;
ii) masking of participants, trialists and outcome
assessors;
iii) exclusion of participants after randomisation and
proportion and reasons for losses at follow-up.
2. Participants
i) country of origin and study setting;
ii) sample size;
iii) age;
iv) gender;
v) inclusion and exclusion criteria.
3. Intervention
i) type;
ii) dose and frequency;
iii) duration of intervention in follow-up.
4. Control
i) type;
ii) dose and frequency;
iii) duration of intervention in follow-up.
5. Outcomes: primary and secondary outcomes mentioned in
the Types of outcome measures section of this review and
categorised and grouped accordingly: short term (less than 12
months) data at 3, 6 and 12 months and medium to long term
(over 1 year).
If stated in the trial reports, we recorded the sources of funding of
any of the included studies.
The review authors used this information to help them assess clin-
ical heterogeneity and the external validity of any included trials.
Assessment of risk of bias in included studies
Two authors (VJ, ZF) independently graded the selected trials us-
ing a simple contingency form and followed the domain-based
evaluation described in Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Interventions 5.0 (Higgins 2009a). The au-
thors compared evaluations and discussed and resolved any incon-
sistencies in these evaluations.
The authors assessed the following domains as ’Yes’ (i.e. low risk
of bias), ’Unclear’ (uncertain risk of bias) or ’No’ (i.e. high risk of
bias):
1. sequence generation;
2. allocation concealment;
3. blinding (of participants, personnel and outcome assessors);
4. incomplete outcome data addressed;
5. free of selective outcome reporting;
6. free of other bias.
The authors categorised the risk of bias in any included studies
according to the following:
• low risk of bias (plausible bias unlikely to seriously alter the
results) if all criteria met;
• unclear risk of bias (plausible bias that raises some doubt
about the results) if one or more criteria assessed as unclear; or
• high risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more criteria not met.
We report these assessments for each trial in the tables (Risk of
bias in included studies) in the review.
Measures of treatment effect
For dichotomous outcomes, we planned to express results as odds
ratios (OR) with 95% confidence intervals (CI). For continuous
outcomes, we calculated themeandifference (MD);wewould have
calculated the standardized mean difference (SMD) if different
measurement scales had been used. We planned to express any
time-to-event outcomes data as ORs or hazards ratios.
Unit of analysis issues
We included trials with a parallel group design, such that par-
ticipants were randomised to either intervention or control with
subsequent analysis at individual allocation level. Unit of analysis
issues can arise with cross-over trials and therefore we decided not
to include end-of-trial data from these trials because the effects
of vitamin K on bone metabolism are likely to be long-term and
an appropriate wash-out period cannot be defined. However, we
planned to include any data reported from the first intervention
period.
Dealing with missing data
We were only able to contact the investigators from one of the
trials (Drury 2008). We obtained individual patient data which
we have included in the analysis.
Assessment of heterogeneity
As we were only able to include two trials in this review, we did
not assess heterogeneity; but in future updates of this review, if
we are able to include further trials, we will apply the following
methods of assessment.
We will assess clinical diversity between the trials by examining
the trial characteristics, the similarity between the types of par-
ticipants, the interventions and the outcomes as specified in the
inclusion criteria.
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We will assess statistical heterogeneity using a Chi2 test and the I
2 statistic, where I2 values of 30% to 60% indicate moderate to
high, 50% to 90% substantial and 75% to 100% considerable het-
erogeneity. We will consider heterogeneity to be significant when
the P value is less than 0.10 (Higgins 2003).
Assessment of reporting biases
The paucity of trials included in this review did not permit an as-
sessment of publication bias. If we had identified a sufficient num-
ber of trials for inclusion in this review (at least 10), we would have
assessed publication bias according to the recommendations on
testing for funnel plot asymmetry as described in section 10.4.3.1
of the Cochrane Handbook for Systematic Reviews of Interventions
version 5.0 (updated September 2009) (Higgins 2009b). If we had
then identified asymmetry, we would have tried to assess other
possible causes and explored these further in the Discussion sec-
tion of the review, if appropriate.
Data synthesis
Two review authors (VJ and ZF) analysed the data in Review
Manager 5 (RevMan 2008) and reported them as specified in
Chapter 9 of the Cochrane Handbook for Systematic Reviews of
Interventions 5.0 (updated September 2009) (Higgins 2009c).
Althoughwe included two trials in this review, wewere only able to
report reliable data from one of them (Drury 2008) and therefore
did not carry out a meta-analysis. If at a later date we include
further trials in this review, we will apply the following methods
of data synthesis. When we include sufficient numbers of trials
investigating similar interventions, we will conduct the analysis in
RevMan (RevMan 2008). In general, we will use the fixed-effect
model; but if there is substantial clinical diversity, we will use the
random-effects model with trials grouped by action.
Subgroup analysis and investigation of heterogeneity
Lack of data did not permit a subgroup analysis, but in future
updates and if further data become available we plan to carry out
the following subgroup analyses:
1. cumulative dose (as per kg body weight per day) of vitamin
K2;
2. route of administration (oral or parenteral);
3. baseline plasma level of vitamin K1 (subnormal versus
normal);
4. presence or absence of any of the following: pancreatic
insufficiency, liver dysfunction, bowel resection or prolonged
usage of antibiotics and chronic steroid administration;
5. mean 25OH vitamin D level.
Sensitivity analysis
In view of the low number of trials included in this review, a
sensitivity analysis was not possible. For future updates and if we
are able to include sufficient trials, we will undertake sensitivity
analyses to assess the robustness of our review results by repeating
the analysis with the following adjustments:
• exclusion of trials with unclear or inadequate allocation
concealment;
• exclusion of trials with unclear or inadequate blinding of
outcomes assessment;
• exclusion of trials with unclear or inadequate completeness
of follow-up;
• exclusion of quasi-randomised trials.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
The electronic searches retrieved references to nine trials. After
examination of the titles and abstracts of these references, all of
those which did not match our inclusion criteria and were clearly
ineligible were eliminated from the review. Full text copies of the
remaining potentially eligible trials were obtained and subjected
to further evaluation. The review authors discussed the eligibility
of these trials, resolved any remaining uncertainties by consensus.
Two trials were included (Beker 1997;Drury 2008), five trials were
excluded (Cornelissen 1992;Grey 2008;Mosler 2003;Nicolaidou
2006;Wilson 2001), and two trials are awaiting classification until
we obtain further information from the trialists (van Hoorn 2003;
van Hoorn 2008).
Our search of the clinical trials database (clinicaltrials.gov) re-
trieved an additional ongoing trial which will be assessed for in-
clusion as soon as it has been published (Kuitert 2010).
Included studies
Two trials, neither ofwhich addressed any of our primary outcomes
andonly reported on twoof the secondary outcomeswere included
in this review. Albeit these two trials were assessed as having a
moderate risk of bias, and provided limited data, it was considered
that their inclusion and the reporting of their results would provide
at least some evidence towards answering this research question.
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One of the trials was cross-over in design, but did not include
a wash-out period and thus the potential risk of bias as a conse-
quence of the carry-over of treatment effect could not be ruled out
(Beker 1997). Although trials with a cross-over designwere eligible
for inclusion in this review, we had specified that only data from
the first intervention period would be used. Unfortunately, the
trial investigators only provided an analysis across both treatment
periods and, even though we were unable to contact the authors
to obtain the first period data, this trial has been included in the
review but it has not been possible to enter the data into a meta-
analysis.
The second trial included in this review was a dose-ranging ran-
domised controlled trial which reported some data for two of our
secondary outcomes, but these were presented as graph-plots from
which we were unable to obtain precise data (Drury 2008). Af-
ter successful contact with the principal investigator via electronic
mail we received the relevant individual patient data for these two
outcomes and have presented them in this review.
Characteristics of the trial setting and investigators
Both were single centre trials, one was conducted at the Montreal
Children’s Hospital CF Clinic in Canada (Drury 2008), and the
other was carried out at the CF Clinic of the Children’s National
Medical Center (CNMC), Washington DC, USA (Beker 1997).
Although the overall duration of the two trials differed, the ac-
tive treatment period was the same (i.e. one month). Thus, in
the cross-over trial, the participants were allocated to either active
intervention or no-treatment control for a four-week period and
then crossed over for a further four weeks but without undergoing
a wash-out period (Beker 1997).
The providers of care in both trials were hospital staff and the
assessors of outcomes were the investigators and other healthcare
providers (Beker 1997; Drury 2008).
Characteristics of the participants
The total sample size comprised of 32 participants between the
ages of 8 and 35 years. In the Beker study, the diagnosis of CF was
confirmed by duplicate sweat test (Beker 1997). Although Drury
did not report the method used to confirm the diagnosis of CF, it
is most probable that participants with CF were enrolled in this
trial (Drury 2008).
All of the participants in the Beker trial were pancreatic insuffi-
cient, as documented by previous fecal fat measurement, and they
received replacement therapy of 750 to 200 units of lipase/kg of
body weight at meal times during the course of the trial (Beker
1997). The investigators in the Drury trial reported that only pan-
creatic insufficient participants were included, but provided no
further details (Drury 2008). Participants with liver disease (diag-
nosed by ultrasound, liver function tests or hepatomegaly or both)
and those who were taking supplemental therapeutic vitamin K to
treat coagulopathies at enrolment were excluded from both trials
(Beker 1997; Drury 2008).
Characteristics of the interventions
The active intervention in the Beker trial consisted of 5 mg oral
vitamin K1 supplementation per week and the control was no
supplementation for four weeks; participants then crossed over
for a second four-week period (Beker 1997). Compliance with
the intervention by participants was verified by the trial coordi-
nator at each visit. Oral antibiotic medications of cephalosporin;
sulfamethoxazole; erythromycin as well as concomitant usage of
bronchodilators and standard multivitamins and 200 to 400 IU
vitamin E were allowed during the course of the trial.
The participants in the Drury trial were randomised to either the
orally administered injectable formulation of vitaminK1phytona-
dione of 1 mg/day (diluted to 1 mg/ml) or the 5 mg/day dose
(Drury 2008).
Characteristics of the outcome measures
None of the primary outcomes specified in the protocol for the
review were considered in either of the included trials (Beker
1997; Drury 2008). Both trials carried out assessments of plasma
VitaminK1 levels and serumundercarboxylated osteocalcin levels;
these were measured at entry and at the completion of the trial by
Drury (Drury 2008), and at the end of each period by Beker (Beker
1997). Dietary intake records to estimate the extent of dietary
contribution of Vitamin K1 were maintained by the participants
in one trial (Beker 1997). The vitamin K1 data of foods were
analysed using Nutritionist III software, the database, however,
did not have complete vitamin K1 data for many foods.
Excluded studies
Five trials were excluded from the review since these were not ran-
domised controlled trials. Further information about the reasons
for exclusion of trials is available in the Excluded studies table.
Risk of bias in included studies
The risks of bias for the two included trials in this review were
classified as previously described (Assessment of risk of bias in
included studies).
Both included trials were judged as having an ’unclear’ risk of bias
overall (Beker 1997; Drury 2008). These assessments were to a
certain extent based on the inadequate reporting of several of the
criteria that are considered to be important in the evaluation of
methodological rigour in terms of trial design and conduct.
For further details see the risk of bias tables in Characteristics of
included studies, the risk of bias graph (Figure 1) and the risk of
bias summary (Figure 2).
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Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The methods used to generate the allocation sequence were not
reported in either trial. Moreover, neither of the trials described
how the allocation sequence was concealed, which did not allow
us to determine whether intervention allocations could have been
foreseen in advance of, or during, enrolment. Inadequate reporting
quality did not permit a clear judgement to be made for both
domains in either of the included trials (Beker 1997;Drury 2008).
Blinding
The measures used to blind trial participants and personnel from
knowledge of which intervention a participant received or any in-
formation relating to whether the intended blinding was effective
were not reported in either trial (Beker 1997; Drury 2008). How-
ever, whilst it may be accepted that blinding of participants and
investigators in the Beker trial may not have been feasible, it was
unclear if the assessors of the outcomes were adequately blinded
(Beker 1997). Therefore the judgement given for this domain in
both trials was ’unclear’.
Incomplete outcome data
There were no withdrawals and no missing or incomplete data
in the Beker trial (Beker 1997); and the only missing data in the
Drury trial was as a result of the inability of the investigators to
make the final outcome assessment for one participant (Drury
2008). Therefore, we judge there to be a low risk of bias from
incomplete outcome data in both trials.
Selective reporting
Although neither trial protocols were available, based on infor-
mation presented in the methods sections of each of the reports,
the investigators appear to have reported on all of their stated
objectives and expected outcomes, a number of which were pre-
specified inclusion criteria for this systematic review (Beker 1997;
Drury 2008). We therefore judge there to be a low risk of bias
from selective reporting for these trials.
Other potential sources of bias
Insufficient information was provided in the reports to assess
whether any other important risk of bias exists, and therefore the
judgement for this domain in both trialswas ’unclear’ (Beker 1997;
Drury 2008).
Effects of interventions
Primary outcomes
None of the primary outcomes specified in the protocol for this
reviewwere considered in either of the included trials (Beker 1997;
Drury 2008).
Secondary outcomes
1. Nutritional parameters
These were not considered in either of the included trials (Beker
1997; Drury 2008).
2. Adverse events
No adverse events were reported in either of the trials (Beker 1997;
Drury 2008).
3. Serum levels
The Drury trial was under-powered (Drury 2008). Even though
we had managed to obtain individual patient data, the small num-
ber of participants and the degree of baseline imbalance in vita-
min K and undercarboxylated osteocalcin levels (both within and
between the groups) did not support analysis of the magnitude
of individual response to treatment or control, i.e. the measure of
change from baseline. Although it is likely that baseline imbalance
may reflect the clinical variability of CF, neither report provided
sufficient clinical detail of the participants to enable any assessment
of the degree of variability in presentation of CF (Beker 1997;
Drury 2008). Therefore, the data for both of these outcomes have
been presented in the analysis as the end of trial mean response
for the total number of participants in each of the treatment and
control groups. We also report the baseline means and SDs along-
side the end of trial values in the additional tables (Table 1; Table
2).
In the Beker trial, the data for this outcome were analysed across
both treatment periods and therefore we only report the end of
trial data narratively (Beker 1997). We advise caution in its inter-
pretation and in any comparison with data from the other trial
included in this review.
a. Serum undercarboxylated osteocalcin (ucOC)
In the Drury trial, all of the participants had elevated (in excess of
21%) concentrations of ucOC before supplementation, but these
levels were reduced after one month of vitamin K1 supplementa-
tion (Drury 2008). The overall level of ucOC decreased from a
median of 46.8% to 29.1%, and the undercarboxylated osteocal-
cin levels decreased and returned to levels within the normal range
in three (one in the 5 mg/day group, two in the 1 mg/day group)
out of the 13 participants by the end of the trial. The mean end
of trial difference in ucOC between the two intervention groups
was -2.20 (95% CI -14.33 to 9.93) (Analysis 1.1).
There was no evidence of any difference between the 5mg/day and
the 1 mg/day vitamin K dosage in terms of statistically significant
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effect on ucOC levels at the end of the one-month trial period
(Drury 2008).
In the Beker trial, all of the participants had increased serum un-
dercarboxylated osteocalcin concentrations (ucOC) at enrolment
and prior to supplementation (Beker 1997). It was reported that
following supplementation and by the end of the trial themajority
had successfully achieved the normal reference mean levels (21%)
of ucOC (Beker 1997).
b. ucOC/cOC (carboxylated osteocalcin) ratio (UCR)
This was not evaluated in either of the trials (Beker 1997; Drury
2008).
4. Vitamin K-specific laboratory outcomes
a. Plasma level of vitamin K1
In the Drury trial, the baseline vitamin K levels in seven out of the
14 participants were sub-optimal (defined as less than 0.3 nmol/
L) (Drury 2008). The paper reported that serum vitamin K levels
appeared to improve significantly (P < 0.001) with supplementa-
tion, rising into the normal range in all of the participants who
were below the optimum level. There was no statistically signifi-
cant difference in effect between the 5 mg/day and the 1 mg/day
vitamin K dose; MD -4.46 (95% CI -12.65 to 3.73) (Analysis
1.2).
In the Beker trial, a substantial number of the participants had
below normal serum vitamin K levels at trial entry (Beker 1997).
Although the mean concentration of plasma vitamin K was higher
in the supplemented group, in only less than half of the total
number of participants were these levels reportedly brought into
the normal range after supplementation with the 5mg dose (Beker
1997).
b. Proteins induced by vitamin K absence or antagonism
factor II (PIVKA II) levels
Drury did not consider or report on this outcome (Drury 2008).
In the Beker trial PIVKA-II concentrations were elevated prior
to supplementation and almost one third of the participants had
PIVKA-II levels within the normal range (≤ 2 ng/ml) following
supplementation (Beker 1997).
D I S C U S S I O N
Summary of main results
The results from both of the included trials could not be pooled
and entered into a meta-analysis; however, both trials reported an
increase in serum vitamin K levels, and a decrease in the undercar-
boxylated osteocalcin levels which returned to normal following
supplementation with oral vitamin K 1 mg/day for one month.
There did not appear to be any significant difference in these out-
comes when a dose of 1 mg/day was compared with 5 mg/day in
the Drury trial (Drury 2008). The PIVKA levels also showed a
decrease and a return to normal in the Beker trial following sup-
plementation (Beker 1997).
Overall completeness and applicability of
evidence
The noticeable absence in the included trials of any assessments
of important clinical outcomes related to coagulopathy or growth
and improvement in quality of life as a result of vitamin K sup-
plementation does somewhat limit the overall completeness and
ultimately the generalisability of the evidence to the wider CF
population. Equally, the short duration and follow-up of the in-
cluded trials does not permit any conclusions to be made about
the longer-term benefits and any potential harms of vitamin K
supplementation.
Future research should aim to close this gap in the evidence by
focusingmore closely on some of the patient-relevant andpreferred
outcomes rather than solely on biochemical laboratory analyses.
Quality of the evidence
The two trials included in this review were underpowered and
of short duration which was illustrated by the wide confidence
intervals in the comparisons of treatment effect and reflected the
degree of imprecision in these results (Beker 1997; Drury 2008).
Some of the practical and methodological difficulties faced by
investigators of this research question were highlighted in these
trials. The key factors which are likely to have had a degree of
impact on the quality level of the evidence for the outcomes sought
in this review can be linked to the design and implementation of
the included trials, and in particular to the effective concealment
of the allocation sequence and adequate blinding of investigators
and outcome assessors.
Potential biases in the review process
Although it would be not unreasonable to assume that the compre-
hensive electronic searches employed in this review will have iden-
tified all existing randomised controlled trials and thereby helped
to limit bias in the conduct of this review, the absence of any other
published randomised trials over the intervening ten years between
the two included trials and their scant contribution to the out-
comes specified for this review, might presuppose an indication of
publication bias.
Agreements and disagreements with other
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studies or reviews
Several trials have indicated a degree of support for the requirement
of supplementation in addition to emphasising the comparative
safety of oral supplementation with vitamin K in people with CF
(Beker 1997; Borowitz 2002; Ramsey 1992; Sinaasappel 2002);
but there is no agreement amongst the trials about the dosage of
supplementation. However, there is some concern that the ade-
quacy of dosing based on measurement of vitamin K levels may be
inaccurate and that PIVKA levels and ucOC levels may be better
indicators of effectiveness of supplementation. Some trials suggest
a complimentary role for quantified dietary intake of vitamin K
in people with CF (Dougherty 2010). This review did not show
anything conclusively to agree or disagree with these trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
People with CF are at risk of vitamin K deficiency. Routine sup-
plementation along with the other fat soluble vitamins is common
clinical practice; however, there appears to be very little consensus
about the exact dosage that should be prescribed. Until further evi-
dence is available supplementation should continue to follow pub-
lished ECFS and CFF guidelines (Borowitz 2002; Cystic Fibrosis
Trust 2002; Sinaasappel 2002) and be guided by monitoring of
the PIVKA or ucOC levels at annual clinical reviews.
Implications for research
There is now a better understanding of the important effect of
vitamin K on gamma-carboxylation of osteocalcin synthesized in
the bones over and above its well-acknowledged requirement for
synthesis of coagulation proteins in the liver. Well-designed ran-
domised controlled trials are still needed to determine the impact
of vitamin K on the outcomes relevant to bone health in addition
to routine supplementation and its benefits in people with CF.
Research in this area is currently limited and long-term and large-
scale trials are needed to provide clear answers to these issues. Ad-
ditional issues that need to be considered are the sensitivity and
reliability of markers for vitamin K deficiency, as well as the diag-
nostic accuracy and associated costs of laboratory equipment and
tests.
Thus randomised controlled trials of vitamin K supplementa-
tion should be placebo-controlled trials of parallel-design involv-
ing both children and adults (considered separately). Outcomes
should include clinical measures (e.g. coagulation effects), bone
measures (density scans) and biochemical markers. In addition pa-
tient-orientated measures such as quality of life and patient sat-
isfaction should also be evaluated. Possible adverse events should
also be specifically recorded and reported.
Further research recommendations based on the EPICOT format
(Brown 2006) are presented in the additional tables (Table 3).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beker 1997
Methods Randomised cross-over trial (2 periods of 4 weeks).
CF Clinic Children’s National Medical Center (CNMC), Washington DC.
No date specified.
Participants Randomised: N = 18 (8 male, 10 female); mean age 20 years (Range 13 - 35 years)
Inclusion criteria
• confirmed diagnosis of CF by duplicate sweat test
• clinically stable as determined by physical exam; afebrile
• moderate lung disease based on an average radiograph score of 15 using the
Brasfield scoring method
• within or above the fifth NCHS height percentile for age and body mass index
(BMI) ≥20
• AST/ALT levels within the normal range, and normal plasma albumin levels
Exclusion criteria
• without cholestasis or overt liver disease
• elevated AST/ALT
Withdrawal or loss to follow-up: None reported.
Interventions Intervention: 5 mg oral vitamin K1 supplementation per week.
Control: no supplementation.
4 weeks of first treatment then crossed over to the other treatment for a second 4-week
period
Concomitant medications permitted: cephalosporin (13); sulfamethoxazole (3); ery-
thromycin (1); bronchodilators; standard multivitamins and 200 - 400 IU vitamin E
Outcomes Primary outcomes: none reported
Secondary outcomes (assessments at entry and end of each trial period)
• plasma vitamin K1 and vitamin K1-2,3 epoxide
• plasma PIVKA-II
• serum osteocalcin
3-day dietary intake records were completed during each treatment period, but these did
not correspond with the nutritional parameters sought as secondary outcomes for this
review
Patient compliance was verified by the trial coordinator at each visit
Notes Randomised cross-over trial, vitamin K supplementation compared with no treatment.
No wash-out period with a potential carry-over of treatment effect. No first-period data
available
“Supported in part by grants from the Board of Lady Visitors, Children’s National Med-
ical Center, Washington, DC, and the University of Maryland, College Park, Maryland.
”
Risk of bias
Bias Authors’ judgement Support for judgement
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Beker 1997 (Continued)
Adequate sequence generation? Unclear risk Quote: “randomly assigned” Page 512
Comment: insufficient information to
make a clear judgement of ’Yes’ or ’No’
Allocation concealment? Unclear risk Not reported.
Probably not done.
Blinding?
All outcomes
Unclear risk Participants: not possible; control was ’no
treatment’.
Healthcare providers: not possible; control
was ’no treatment’
Outcomes assessors and data analysts: un-
clear.
Comment: overall judgement unclear.
Incomplete outcome data addressed?
All outcomes
Low risk There were no withdrawals and no missing
or incomplete data.
Free of selective reporting? Low risk Although the protocol was not available all
relevant outcomes appear to have been ad-
dressed
Free of other bias? Unclear risk Quote: “Supported in part by grants from
the Board of Lady Visitors, Children’s Na-
tional Medical Center, Washington, DC,
and the University of Maryland, College
Park, Maryland.”
Comment: it is unclear to what extent the
support provided may have had on the re-
sults of this study. Insufficient information
to assess whether an important risk of bias
exists
Drury 2008
Methods Randomised control trial over 1-month period.
Montreal Children’s Hospital Cystic Fibrosis Clinic, Canada.
Date not specified.
Participants Randomised: N = 14; 8 to 18 years, gender unspecified.
Inclusion criteria
• CF with pancreatic insufficiency. Method of CF diagnosis unreported
Exclusion criteria:
• known liver disease (diagnosed by ultrasound, liver function tests and/or
hepatomegaly)
• supplemental therapeutic vitamin K to treat coagulopathies
Withdrawal or loss to follow-up: missing data (1) from 5 mg group at final assessment.
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Drury 2008 (Continued)
Interventions Intervention: oral administration of injectable formulation of vitamin K1 phytonadione
(Sandoz Canada, Boucherville, Qc) diluted 1 mg/1 ml. Dose 1 mg/day for 1 month.
Control: identical but dose 5 mg/day for 1 month.
Outcomes Primary outcomes: none reported
Secondary outcomes
• plasma vitamin K1 levels
• serum undercarboxylated osteocalcin levels
Measured at the beginning of the trial and at the end of 1 month
Notes This project was funded by the Canadian CF Foundation.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Quote: “were randomised to receive either
1 mg/day, or 5 mg/day” Page 458
Comment: insufficient information to
make a clear judgement of ’Yes’ or ’No’
Allocation concealment? Unclear risk Not reported.
Probably not done.
Blinding?
All outcomes
Unclear risk Participants: not reported.
Healthcare providers: unclear.
Outcomes assessors and data analysts: un-
clear.
Comment: overall judgement unclear.
Incomplete outcome data addressed?
All outcomes
Low risk Quote “One subject in the 5 mg group
lost consciousness at the time of the second
blood procurement”. Pg 458
Comment: incomplete data for one partic-
ipant.
Free of selective reporting? Low risk The stated objectives of the trial appear to
match the listed outcomes. There was no
evidence of selective reporting of outcomes
Free of other bias? Unclear risk Quote: “This project was funded by the
Canadian CF Foundation”.
Comment: it is unclear to what extent the
support provided may have had on the re-
sults of this trial. Insufficient information
to assess whether an important risk of bias
exists
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ALT: alanine aminotransferase
AST: aspartate aminotransferase
BMI: body mass index
CF: cystic fibrosis
IU: international units
NCHS: National Center for Health Statistics
PIVKA-II: proteins induced by vitamin K absence or antagonism factor II
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cornelissen 1992 Non-RCT.
Grey 2008 Non-RCT.
Mosler 2003 Non-RCT.
Nicolaidou 2006 Non-RCT, non-CF control group.
Wilson 2001 Uncontrolled study, non-RCT.
CF: cystic fibrosis
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
van Hoorn 2003
Methods Case controlled study
Participants CF patients
Interventions Vitamin K in 3 different groups - no supplements, low supplements or high supplements
Outcomes serum ucOC level
Notes Awaiting inclusion until the response form the authors about randomisation in the study
17Vitamin K supplementation for cystic fibrosis (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
van Hoorn 2008
Methods Randomised controlled study
Participants 26 patients not receiving vitamin K supplementation before
Interventions 0.1 mg and 1 mg vitamin K supplementation for 2 years
Outcomes ucOC levels and BMD
Notes Only abstract is available now, likely to be included, but we will consider after we get further information from the
investigators
BMD: bone mineral density
CF: cystic fibrosis
ucOC: undercarboxylated osteocalcin
Characteristics of ongoing studies [ordered by study ID]
Kuitert 2010
Trial name or title Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in
adolescents and adults with CF
Methods RCT
Participants Patients with a diagnosis of CF (positive sweat test or genotype testing) aged over 16 years (post pubertal-stage
IV Tanner), either sex, pancreatic insufficient (i.e. with a positive faecal elastase test, and requiring pancreatic
enzyme supplementation) and no overt liver disease
Interventions 10 mg of menadiol phosphate (water soluble form of vitamin K) once daily orally for 12 months versus
placebo
Outcomes • difference in the ratio of undercarboxylated osteocalcin to total osteocalcin, measured prior to
supplementation starting and at the end of the 12 months supplementation
• total osteocalcin
• undercarboxylated osteocalcin
• N Terminal X (marker of bone resorption)
• bone specific alkaline phosphatase
• serum vitamin D
• calcium
• DEXA scan z and t scores of lumbar spine and femoral neck (scores adjusted for age, height and sex)
measured prior to supplementation starting and at the end of the 12 months supplementation
Starting date 09/05/2008
Contact information Lieske Kuitert,Department ofRespiratoryMedicine, LondonChestHospital, BonnerRoad, E29JX, London,
United Kingdom
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Kuitert 2010 (Continued)
Notes
CF: cystic fibrosis
DEXA: dual energy x-ray absorptiometry
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Comparision of 1 mg/day vs 5 mg/day oral vitamin K
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serum undercarboxylated
osteocalcin levels
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Serum vitamin K levels 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Comparision of 1 mg/day vs 5 mg/day oral vitamin K, Outcome 1 Serum
undercarboxylated osteocalcin levels.
Review: Vitamin K supplementation for cystic fibrosis
Comparison: 1 Comparision of 1 mg/day vs 5 mg/day oral vitamin K
Outcome: 1 Serum undercarboxylated osteocalcin levels
Study or subgroup Vitamin K 1 mg/day Vitamin K 5 mg/day
Mean
Difference
Mean
Difference
N Mean(SD)[percentage] N Mean(SD)[percentage] IV,Fixed,95% CI IV,Fixed,95% CI
Drury 2008 7 28 (8.26) 6 30.2 (13.09) -2.20 [ -14.33, 9.93 ]
-20 -10 0 10 20
Favours 1 mg/day Favours 5 mg/day
20Vitamin K supplementation for cystic fibrosis (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Comparision of 1 mg/day vs 5 mg/day oral vitamin K, Outcome 2 Serum
vitamin K levels.
Review: Vitamin K supplementation for cystic fibrosis
Comparison: 1 Comparision of 1 mg/day vs 5 mg/day oral vitamin K
Outcome: 2 Serum vitamin K levels
Study or subgroup Vitamin K 1 mg/day Vitamin K 5 mg/day
Mean
Difference
Mean
Difference
N Mean(SD)[nmol/L] N Mean(SD)[nmol/L] IV,Fixed,95% CI IV,Fixed,95% CI
Drury 2008 7 2.52 (2.61) 6 6.98 (9.95) -4.46 [ -12.65, 3.73 ]
-10 -5 0 5 10
Favours 1 mg/day Favours 5 mg/day
A D D I T I O N A L T A B L E S
Table 1. Serum undercarboxylated osteocalcin (ucOC) percentage (Drury 2008)
Dose n UcOC %
Baseline mean (SD)
UcOC %
End of study mean (SD)
1 mg/day 7 46 (14.4) 28 (8.26)
5 mg/day 6 47.6 (9.45) 30.2 (13.09)
SD: standard deviation
ucOC: undercarboxylated osteocalcin
Table 2. Serum vitamin K levels (Drury 2008)
Dose n Serum vitamin K levels (nmol/L)
Baseline mean (SD)
Serum vitamin K levels (nmol/L)
End of study mean (SD)
1 mg/day 7 0.28 (0.25) 2.52 (2.61)
5 mg/day 6 0.15 (0.19) 6.98 (9.95)
SD: standard deviation
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Table 3. Research recommendations based on a gap in the evidence on Vitamin K supplementation for cystic fibrosis
Core elements Issues to consider Status of research for this review
Evidence
(E)
What is the current state of evidence? A systematic review found only limited high quality
evidence in relation to the effectiveness or otherwise of
vitamin K supplementation for people with CF
Population
(P)
Diagnosis, disease stage, comorbidity, risk factor, sex,
age, ethnic group, specific inclusion or exclusion crite-
ria, clinical setting
Any age group with a diagnosis of CF (defined by sweat
test or genetic testing or both). Pancreatic insufficient
Intervention
(I)
Type, prognostic
factor
All preparations of vitamin K used as a supplement at
any dose and for any duration
Comparison
(C)
Type, prognostic factor Placebo with a dose, frequency, duration comparable to
the intervention, or no supplementation.
Trials comparing different doses and dose regimens of
vitamin K will also be considered.
Compliance to be recorded via pill counts and any con-
comitant medications
Outcome
(O)
Which clinical or patient related outcomes will the re-
searcher need to measure, improve, influence or accom-
plish?
Which methods of measurement should be used?
Clinical outcomes related to:
• coagulopathy
• bone formation ie bone mineral density, DEXA
scans
• nutritional parameters; weight, height, BMI
Biochemical analysis:
• serum levels: serum ucOC/cOC ratio
• vitamin K-specific laboratory outcomes: plasma
level of vitamin K1 (measured by HPLC), PIVKA II
levels (measured by ELISA)
Quality of life:
• CFQ-R (Quittner 2000)
• CFQoL (Gee 2000)
Adverse events
Data type: continuous and dichotomous
Time stamp
(T)
Date of literature search or recommendation 15 April 2010.
Study type What is the most appropriate study design to address
the proposed question?
RCT (adequately powered/large sample size, sufficient
duration)
Methods: concealment of allocation sequence
Blinding: participants and investigators, but if not fea-
sible then outcomes assessors and data analysts should
be blinded.
Setting: CF Clinic
BMI: body mass index
CF: cystic fibrosis
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cOC: carboxylated osteocalcin
DEXA: dual energy X-ray absorptiometry
ELISA: enzyme-linked immunosorbent assay
HPLC: high performance liquid chromatography
PIVKA-II: proteins induced by vitamin K absence or antagonism factor II
RCT: randomised controlled trial
ucOC: undercarboxylated osteocalcin
A P P E N D I C E S
Appendix 1. Glossary
Term Meaning
bisphosphonate a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases
carboxylation a chemical reaction in which a carboxylic acid group is introduced in a substrate
coagulopathy a defect in the body’s mechanism for blood clotting
cofactor a non-protein chemical compound that is bound to a protein and is required for the protein’s
biological activity
gamma-glutamyl carboxylase an enzyme that catalyses the gamma-carboxylation of glutamic acid residues in bone matrix proteins
such as osteocalcin
haemostasis a complex process which causes the bleeding process to stop
homozygous in genetics having identical alleles for a single characteristic
mucosal bleeding bleeding in mucus membranes
osteoblast mononucleate cells that are responsible for bone formation
post-translational modification the chemical modification of a protein after its translation (the production of proteins by decoding
messenger RNA); the post-translational modification extends the range of functions of the protein
subclinical describes an early stage or mild form of a medical condition, where no symptoms are detectable
subcutaneous bleeding bleeding under the skin
23Vitamin K supplementation for cystic fibrosis (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
WH A T ’ S N E W
Last assessed as up-to-date: 14 October 2010.
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